Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
et al., NCT04439006, NCT04439006, Sep 2022
10 patient ibrutinib late treatment RCT with results not reported over 3 years after completion.
Woyach et al., 20 Sep 2022, Randomized Controlled Trial, USA, trial NCT04439006 (history).
Late treatment
is less effective
is less effective
